Search

Displaying results 6901 - 6910 of 6949 in total
  1. Drug

    Latiglutenase

    go.drugbank.com/drugs/DB06326
    Investigational

  2. Drug

    RDEA806

    go.drugbank.com/drugs/DB05228
    Investigational

    RDEA806 is a new HIV non-nucleoside reverse transcriptase inhibitor (NNRTI) with a high genetic barrier to resistance and a broad spectrum of activity.

  3. Drug

    Tifuvirtide

    go.drugbank.com/drugs/DB05413
    Investigational

    Tifuvirtide is the first members of a new class of anti-HIV drugs which is also called fusion inhibitors. It has received fast-track designation from the FDA and is in Phase I/II clinical testing.

  4. Drug

    P54

    go.drugbank.com/drugs/DB05451
    Experimental

    P54 reduces the inflammation associated with cancer/tumors, Crohn's disease, inflammatory bowel disease, osteoarthritis, and ulcerative colitis. It inhibits the induction of the enzyme NFkB, thereby inhibiting downstream inflammatory gen...

  5. Drug

    Enrasentan

    go.drugbank.com/drugs/DB06460
    Experimental

    Categories: Endothelin Receptor Antagonists
  6. Drug

    Amdoxovir

    go.drugbank.com/drugs/DB06619
    Investigational

  7. Drug

    Capravirine

    go.drugbank.com/drugs/DB08502
    Investigational

  8. Drug

    alpha-Pyrrolidinononanophenone

    go.drugbank.com/drugs/DB05531
    Investigational

  9. Drug

    LM-609

    go.drugbank.com/drugs/DB05787
    Experimental

    LM-609 (Vitaxin) is an artificial antibody that targets a protein on the surface of newly forming blood vessels, as well as on certain tumors. In addition to cancer, the protein has been implicated in bone destruction in rheumatoid arthr...

  10. Drug

    PRO-542

    go.drugbank.com/drugs/DB05793
    Investigational

    PRO 542 belongs to a new class of drugs, viral-entry inhibitor, which is intended to prevent HIV from entering and infecting cells. PRO 542 (CD4-immunoglobulin G2) is a tetravalent CD4-immunoglobulin fusion protein that broadly neutraliz...